

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
20 March 2014 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:30 – 9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drug classes during the February 2014 meeting:

- ***Drug Class and Subclass Reviews:***
 - ***Long acting beta agonist/inhaled corticosteroids***
 - ***Pancreatic enzyme products***
 - ***GI-1 amino salicylate subclass***
- ***Designated Newly Approved Drugs***
 - ***Antidepressant 1 - Bupropion 450 mg (ForFivo)***
 - ***Antidepressant 1 - Desvenlafaxine extended release (Khedezla)***
 - ***Antidepressant 1 - Vortioxetine (Brintellix)***
 - ***Antidepressant 1 - Levomilnacipran (Fetzima)***
-
- ***Utilization Management Issues***
 - ***Prior Authorization Criteria***
 - ***Avanafil (Stendra)***
 - ***Mirabegron (Myrbetriq)***
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any

questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.